Are there different kidney outcomes among patients diagnosed with malignant hypertension (mHTN)–associated thrombotic microangiopathy (TMA) who received sacubitril/valsartan compared with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) therapy? This evidence concerns the gene ACE and thrombotic microangiopathy.